Clinical Trial: Effect of Cyclosporine Inhibition of Specific P-glycoprotein and Breast Cancer Resistance Protein Transporters on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers

U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT06892756) titled 'Effect of Cyclosporine Inhibition of Specific P-glycoprotein and Breast Cancer Resistance Protein Transporters on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers' on March 05.

Brief Summary: The main goal of this pharmacokinetic study in healthy volunteers is to evaluate the potential effect of cyclosporine (probe inhibitor of P glycoprotein [P-gp] and breast cancer resistance protein [BCRP] transporters) on CHF6001 (Tanimilast) systemic exposure following single dose administration, by comparing the area under the curve (AUC) from time 0 to the last quantifiable concentration (AUC0 t) and the maximum pl...